Form 4: Repare Therapeutics CEO Sells Shares to Cover Tax Obligations

Repare Therapeutics CEO, Lloyd Mitchell Segal, sold common shares between March 25-27, 2024, to cover tax obligations related to vested restricted stock units.

Summary

• Lloyd Mitchell Segal, the President and CEO of Repare Therapeutics Inc., sold common shares of the company between March 25 and March 27, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 22, 2023.
• A total of 7,950 shares were sold across the three days to cover tax withholding obligations arising from the vesting of 26,183 restricted stock units (RSUs) on January 30, 2024.
• The sales prices ranged from $4.52 to $4.97 per share.
• Following these transactions, Segal directly owns 124,677 common shares and indirectly owns 83,866 shares through Arvala Inc., where he is the sole stockholder.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The stock sales were pre-planned and for tax purposes, but any insider selling can create slight uncertainty.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating they were planned in advance and not based on current market information.
• The sales were to cover tax obligations, which is a common and understandable reason for selling shares.

Negatives

• The CEO selling shares, even for tax purposes, could be perceived negatively by some investors.

Risks

• Continued sales by insiders could put downward pressure on the stock price.
• Investor sentiment could be negatively affected if insider sales are perceived as a lack of confidence in the company's future.

Industry Context

Insider sales are a common occurrence in publicly traded companies, often related to compensation and tax planning. The use of a pre-arranged trading plan is a standard practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• It is common for executives at publicly traded companies, including those in the biotechnology sector like Repare Therapeutics, to utilize 10b5-1 trading plans to manage their stock sales.
• These plans allow insiders to sell shares at predetermined times and prices, helping to avoid accusations of insider trading.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also see regular insider trading activity, often related to stock options and RSU vesting.

Stakeholder Impact

• Shareholders may react neutrally or slightly negatively to the news of insider selling, even if it's for tax purposes.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal.

Key Dates